hyaluronoglucosaminidase has been researched along with Adverse Drug Event in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Haas, JP; Hinze, CH; Speth, F | 1 |
1 trial(s) available for hyaluronoglucosaminidase and Adverse Drug Event
| Article | Year |
|---|---|
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
1 other study(ies) available for hyaluronoglucosaminidase and Adverse Drug Event
| Article | Year |
|---|---|
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
Topics: Cell Membrane Permeability; Child; Dermatomyositis; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hyaluronoglucosaminidase; Immunoglobulins, Intravenous; Immunologic Factors; Immunomodulation; Male; Monitoring, Immunologic; Recombinant Proteins; Subcutaneous Tissue; Treatment Outcome | 2016 |